LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
Rhea-AI Summary
LENZ Therapeutics (Nasdaq: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, has scheduled its third quarter 2024 financial results and business update webcast for November 6, 2024, at 8:00 a.m. EST. The company will host a conference call accessible via phone and webcast, with a replay available on their website for 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – LENZ
In the trading session that priced this news, LENZ declined 2.02%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, November 6, 2024 at 8:00 a.m. EST to report its third quarter 2024 financial results and provide a business update.
To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 7959303. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
